Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Harnessing AlphaFold to reveal hERG channel conformational state secrets.

Khoa Ngo | Pei-Chi Yang | Vladimir Yarov-Yarovoy | Colleen E Clancy | Igor Vorobyov
eLife | 2025

To design safe, selective, and effective new therapies, there must be a deep understanding of the structure and function of the drug target. One of the most difficult problems to solve has been the resolution of discrete conformational states of transmembrane ion channel proteins. An example is KV11.1 (hERG), comprising the primary cardiac repolarizing current, Ikr. hERG is a notorious drug anti-target against which all promising drugs are screened to determine potential for arrhythmia. Drug interactions with the hERG inactivated state are linked to elevated arrhythmia risk, and drugs may become trapped during channel closure. While prior studies have applied AlphaFold to predict alternative protein conformations, we show that the inclusion of carefully chosen structural templates can guide these predictions toward distinct functional states. This targeted modeling approach is validated through comparisons with experimental data, including proposed state-dependent structural features, drug interactions from molecular docking, and ion conduction properties from molecular dynamics simulations. Remarkably, AlphaFold not only predicts inactivation mechanisms of the hERG channel that prevent ion conduction but also uncovers novel molecular features explaining enhanced drug binding observed during inactivation, offering a deeper understanding of hERG channel function and pharmacology. Furthermore, leveraging AlphaFold-derived states enhances computational screening by significantly improving agreement with experimental drug affinities, an important advance for hERG as a key drug safety target where traditional single-state models miss critical state-dependent effects. By mapping protein residue interaction networks across closed, open, and inactivated states, we identified critical residues driving state transitions validated by prior mutagenesis studies. This innovative methodology sets a new benchmark for integrating deep learning-based protein structure prediction with experimental validation. It also offers a broadly applicable approach using AlphaFold to predict discrete protein conformations, reconcile disparate data, and uncover novel structure-function relationships, ultimately advancing drug safety screening and enabling the design of safer therapeutics.

Pubmed ID: 40658102

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: Texas Advanced Computing Center (TACC),
    Id: MCB20010
  • Agency: NHLBI NIH HHS, United States
    Id: U01HL126273
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL128537
  • Agency: NHLBI NIH HHS, United States
    Id: T32 HL086350
  • Agency: National Science Foundation,
    Id: 2032486
  • Agency: NHLBI NIH HHS, United States
    Id: R01HL085844
  • Agency: Pittsburgh Supercomputing Center (PSC),
    Id: PSCA17085P
  • Agency: Pittsburgh Supercomputing Center (PSC),
    Id: PSCA16108P
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL174001
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL085844
  • Agency: University of California Davis School of Medicine,
    Id: Department of Physiology and Membrane Biology Research Partnership Fund
  • Agency: Advanced Cyberinfrastructure Coordination Ecosystem: Services & Support (ACCESS),
    Id: MCB170095
  • Agency: NIH HHS, United States
    Id: OT2OD026580
  • Agency: Pittsburgh Supercomputing Center (PSC),
    Id: PSCA18077P
  • Agency: Pittsburgh Supercomputing Center (PSC),
    Id: MCB160089P
  • Agency: NIH HHS, United States
    Id: OT2 OD026580
  • Agency: NHLBI NIH HHS, United States
    Id: R01HL128537
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL152681
  • Agency: Oracle,
    Id: Oracle for Research fellowship
  • Agency: NHLBI NIH HHS, United States
    Id: T32HL086350
  • Agency: American Heart Association,
    Id: 19CDA34770101
  • Agency: NHLBI NIH HHS, United States
    Id: U01 HL126273
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM116961
  • Agency: NHLBI NIH HHS, United States
    Id: R01HL152681
  • Agency: NHLBI NIH HHS, United States
    Id: R01HL174001

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


PubChem (tool)

RRID:SCR_004284

Collection of information about chemical structures and biological properties of small molecules and siRNA reagents hosted by the National Center for Biotechnology Information (NCBI).

View all literature mentions

OpenEye (tool)

RRID:SCR_014880

Commercial organization which provides molecular modelling and cheminformatics software to the pharmaceutical industry.

View all literature mentions

ColabFold (tool)

RRID:SCR_025453

Software application offers accelerated prediction of protein structures and complexes by combining homology search of MMseqs2 with AlphaFold2 or RoseTTAFold. Used for protein folding.

View all literature mentions